TY - JOUR
T1 - Preclinical and clinical studies with combinations of pemetrexed and gemcitabine
AU - Adjei, Alex A.
PY - 2002/12
Y1 - 2002/12
N2 - The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.
AB - The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.
UR - http://www.scopus.com/inward/record.url?scp=0036984020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036984020&partnerID=8YFLogxK
U2 - 10.1016/s0093-7754(02)70043-2
DO - 10.1016/s0093-7754(02)70043-2
M3 - Review article
C2 - 12571808
AN - SCOPUS:0036984020
SN - 0093-7754
VL - 29
SP - 30
EP - 34
JO - Seminars in oncology
JF - Seminars in oncology
IS - 6 SUPPL. 18
ER -